


# Journal Pre-proof



Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic and immunohistochemical landscapes of a rare case

Divya Aggarwal, MD, DNB, Senior Resident, Parikshaa Gupta, MD, DNB, MIAC, Assistant professor, Prashant Chhabra, MD, Senior Resident, Nitin James Peters, MS, MCh, Assistant Professor, Deepak Bansal, MD, Professor, Radhika Srinivasan, MD, PhD, Professor and Head, Nandita Kakkar, MD, Professor

PII: S1083-3188(20)30293-X

DOI: <https://doi.org/10.1016/j.jpag.2020.07.017>

Reference: PEDADO 2530

To appear in: *Journal of Pediatric and Adolescent Gynecology*

Received Date: 27 May 2020

Revised Date: 6 July 2020

Accepted Date: 27 July 2020

Please cite this article as: Aggarwal D, Gupta P, Chhabra P, Peters NJ, Bansal D, Srinivasan R, Kakkar N, Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic and immunohistochemical landscapes of a rare case, *Journal of Pediatric and Adolescent Gynecology* (2020), doi: <https://doi.org/10.1016/j.jpag.2020.07.017>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of North American Society for Pediatric and Adolescent Gynecology.

1 **Type of the article-** Case Report

2 **Title: Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic and**  
3 **immunohistochemical landscapes of a rare case**

4  
5 **Authors:**

6 **Divya Aggarwal**, MD, DNB, Senior Resident, Department of Cytology and Gynecologic  
7 Pathology, PGIMER, Chandigarh, India

8 **Parikshaa Gupta**, MD, DNB, MIAC, Assistant professor, Department of Cytology and  
9 Gynecologic Pathology, PGIMER, Chandigarh, India

10 **Prashant Chhabra**, MD, Senior Resident, Department of Pediatric Hemato-Oncology,  
11 PGIMER, Chandigarh, India

12 **Nitin James Peters**, MS, MCh, Assistant Professor, Department of Pediatric Surgery,  
13 PGIMER, Chandigarh, India

14 **Deepak Bansal**, MD, Professor, Department of Pediatric Hemato-Oncology, PGIMER,  
15 Chandigarh, India

16 **Radhika Srinivasan**, MD, PhD, Professor and Head, Department of Cytology and  
17 Gynecologic Pathology, PGIMER, Chandigarh, India

18 **Nandita Kakkar**, MD, Professor, Department of Histopathology, PGIMER, Chandigarh,  
19 India

20  
21 **Address for correspondence**

22 **Dr Parikshaa Gupta**  
23 Assistant Professor  
24 Department of Cytology and Gynecologic Pathology  
25 Research 'A' Block  
26 PGIMER, Sector 12  
27 Chandigarh- 160012  
28 Email: parikshaa@gmail.com  
29 Phone- 9914204124

30 **Running Head:** Small cell carcinoma of ovary, hypercalcemic type

31 **Keywords:** Small cell carcinoma ovary; small cell carcinoma ovary, hypercalcemic type;  
32 cytology; histopathology; immunohistochemistry

33 **Abstract word count:** 135

34 **Manuscript word count:** 1624

35 **Number of Figures:** 3

36 **Number of tables:** 1

37 **Title: Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic and**  
38 **immunohistochemical landscapes of a rare case**

39 **Abstract**

40 **Background:** Small cell carcinoma of ovary, hypercalcemia type (SCCOHT), also known as  
41 the malignant rhabdoid tumor of the ovary, is a rare and highly aggressive malignancy  
42 affecting younger women. The pathogenesis involves mutations in *SMARCA4/BRG1* and/or  
43 *SMARCA2/BRM*.

44 **Case:** A 10-year-old girl presented with lower abdominal pain and a mass for the past 2  
45 weeks. She underwent ultrasound-guided fine needle aspiration and core needle biopsy from  
46 the pelvic mass followed by surgery. Based on the characteristic morphologic and  
47 immunohistochemical features, a diagnosis of SCCOHT was rendered. She was started on  
48 chemotherapy, however, succumbed to the disease.

49 **Summary and Conclusion:** SCCOHT is a rare but highly aggressive ovarian malignancy  
50 with poor clinical outcome. A high index of clinical suspicion and adequate knowledge of its  
51 characteristic cytologic, histopathologic and immunohistochemical features are essential for  
52 accurate diagnosis of SCCOHT.

53 **Title: Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic and**  
54 **immunohistochemical landscapes of a rare case**

55 **Introduction**

56 Small cell carcinoma of ovary, hypercalcemic type (SCCOHT) is a rare and aggressive  
57 malignancy affecting women in a wide age range.<sup>1</sup> The pathogenesis involves mutation in  
58 *SMARCA4/BRG1* and/or *SMARCA2/BRM*. The disease follows a rapid downhill course with  
59 majority of the patients showing disease progression despite aggressive treatment. Owing to  
60 the non-specific clinical presentations and overlapping radiologic features, which are often  
61 similar to other ovarian malignancies, establishing a clinical diagnosis of SCCOHT is  
62 extremely challenging. However, two-third of these cases may have associated  
63 hypercalcemia.<sup>2</sup>

64 Definitive diagnosis requires microscopic examination of the tumor tissue.  
65 Histopathologically, the tumor exhibits a highly undifferentiated morphology, mimicking  
66 many other ovarian tumors, which may further compound the diagnostic difficulty.  
67 Immunohistochemistry can help in reaching to an accurate diagnosis in such cases. Lack of  
68 awareness of its characteristic morphologic and immunohistochemical features can often lead  
69 to the tumor being misdiagnosed as other ovarian neoplasms including, include granulosa cell  
70 tumor, small cell carcinoma ovary, pulmonary type (SCCOPT), dysgerminoma, non-  
71 Hodgkin's lymphoma and undifferentiated carcinoma. This often carries significant clinical  
72 implications as the prognosis and therapeutics vary. Additionally, the cytological findings of  
73 this uncommon entity have only been sparsely described in the published literature. Herein,  
74 we present a case of SCCOHT in an adolescent and describe its cytological, histopathological  
75 and immunohistochemical features.

76 **Case report**

77 A 10-year-old girl presented with pain lower abdomen and fever for 15 days and swelling in  
78 the lower abdomen for 7 days. The pain was continuous, dull-aching and fever was  
79 intermittent, low grade. There was no history of respiratory distress, vomiting, bone pain,  
80 bladder or bowel symptoms or other systemic symptoms. Her body weight and height were  
81 below 3 standard deviations for her age with body mass index of 13.57. Clinical examination  
82 revealed a large abdominal mass felt in the left iliac fossa, extending to the umbilical and left  
83 hypogastric regions. Laboratory investigations revealed a haemoglobin of 10.4 g/dl, with  
84 normal leucocyte and platelet counts. Liver and renal function tests were within normal  
85 limits. Tumor markers including alpha fetoprotein and beta-hCG (human chorionic  
86 gonadotropin) were normal. Contrast-enhanced computerized tomography (CECT) of the  
87 abdomen showed a large, heterogeneously enhancing space occupying lesion in the pelvis  
88 measuring 10.5x8.4x6.7 cm, with extensive necrosis and no calcifications. The lesion was  
89 indenting bladder and anterior abdominal wall with preserved interface. Uterus and left ovary  
90 could not be visualised separately. CECT thorax and bone scan were normal.

91 An ultrasound-guided fine needle aspiration cytology (FNAC) was done from the  
92 ovarian mass. The smears prepared were cellular and showed tumor cells in clusters as well  
93 as scattered singly (Figure 1A). Majority of the tumor cells exhibited moderate degree of  
94 nuclear pleomorphism, with coarsely clumped chromatin, small nucleoli and indistinct  
95 cytoplasmic borders (Figure 1B, C). Some of the cells were larger, with moderate to abundant  
96 amount of dense eosinophilic cytoplasm with eccentric nuclei having prominent nucleoli,  
97 imparting a rhabdoid appearance (Figure 1F). Section from the cell-block also recapitulated  
98 similar cytomorphology (Figure 1D-F). Areas of necrosis were also noted in the cell-block  
99 section (Figure 1D). Based on these features, differential diagnoses of rhabdomyosarcoma  
100 and malignant rhabdoid tumor were offered.

101 Immunocytochemistry (ICC) was performed on the cell-block, and the tumor cells  
102 showed positivity for vimentin, CD99 (paranuclear dot positivity) and were negative for  
103 myogenin, myoD1 and desmin (Figure 1G-I). Based on these findings, the possibility of  
104 rhabdomyosarcoma was excluded. True-cut biopsy suggested the possibility of abdominal  
105 primitive neuroectodermal tumour (PNET). Hence, she was started on intergroup INT-0091  
106 protocol for Ewing family of tumours comprising of alternating 2 weekly cycles of VDC  
107 (Vincristine 2mg/m<sup>2</sup>/dose,day1; Doxorubicin 37.5 mg/m<sup>2</sup>/d, day 1 and 2; Cyclophosphamide  
108 1200 mg/m<sup>2</sup>,day1) and IE regimen (Ifosfamide 1800 mg/m<sup>2</sup>/day x 5 days and Etoposide 100  
109 mg/m<sup>2</sup>/day x 5 days) with G-CSF support (5 mcg/kg/d x 6 days). Interval debulking surgery  
110 was planned at week 12 from start of chemotherapy as local control.

111 During interval debulking, the mass was seen to be arising from one of the ovaries.  
112 Subsequently, oophorectomy was performed and omental deposits were biopsied. Grossly,  
113 the specimen showed a tumor measuring 10x6.5x5.5 cm. Outer surface was bosselated with  
114 presence of few areas of haemorrhage. Cut surface revealed solid (90%) and cystic (10%)  
115 areas. Solid areas had a lobulated appearance with grey-white cut surface and areas of  
116 necrosis (Figure 2). Microscopic examination of the representative sections revealed a tumor  
117 with cells arranged in sheets, lobules and focal follicle-like spaces. The cellular morphology  
118 was similar to that seen on FNAC smears. Large areas of necrosis were identified (Figure 3A-  
119 C). Omental deposits were confirmed on microscopy (Figure 3D). On performing  
120 immunohistochemistry, the tumor cells showed positivity for pan-cytokeratin, vimentin,  
121 CD99 (dot-like), WT1 and showed retained nuclear expression for INI1 (Figure 3E-H). FLI1  
122 showed patchy positivity. They were negative for chromogranin and inhibin (Figure 3I).  
123 There was loss of expression of SMARCA4/BRG1 protein in the tumor cells. In view of the  
124 overall clinical, cytomorphological and immunohistochemical features, a final diagnosis of

125 small cell carcinoma of ovary, hypercalcemic type was rendered. Patient was started on  
126 chemotherapy, however, she succumbed to the disease, 7 months after her initial presentation.

## 127 **Discussion**

128 Small cell carcinoma of ovary hypercalcemic type (SCCOHT) in an aggressive malignancy  
129 of ovary with a 5-year-overall survival rate of 10%, first described by Dickersin et al. in  
130 1982.<sup>2,3</sup> It commonly affects women younger than 40 years of age.<sup>4</sup> However, its occurrence  
131 in children is very rare with only a few case reports documenting the same. The youngest  
132 reported case is of a 14-month-old child.<sup>5</sup>

133 Pathogenesis involves sporadic/germline mutations in *SMARCA4/BRG1* and/or  
134 *SMARCA2/BRM*. Rarely, familial association has been reported. Witkowski *et al*, reported 2  
135 families, both with 2 females diagnosed with SCCOHT and carrying germline mutations in  
136 *SMARCA4/BRG1*.<sup>6</sup> A few of these cases may show mutations in *SMARCB1/INI1*, which are  
137 otherwise more commonly associated with malignant rhabdoid tumors elsewhere in the body.

138 Clinically, the disease has non-specific presentations, most common being abdominal  
139 pain and swelling. Two thirds of these patients have associated hypercalcemia.<sup>1</sup> However,  
140 symptoms of hypercalcemia like polyuria, polydipsia, constipation, muscle weakness and  
141 bone pains; have only been reported in less than 5% of these patients.<sup>7</sup> The hypercalcemia  
142 associated with SCCOHT is known to regress following complete surgical excision and re-  
143 appear in cases with recurrence and hence can be used as a potential tumor marker for early  
144 detection of recurrence in such cases.<sup>2,3,8</sup> Serum calcium levels had not been estimated in the  
145 index patient, as a diagnosis of SCCOHT/MRT was not being suspected and she was being  
146 managed initially on the lines of Ewing family of tumors. Radiological features are often non-  
147 specific and similar to those seen in other ovarian malignancies. Majority of these patients  
148 present with a unilateral, solid, large ovarian mass. Bilateral ovarian involvement is rare and

149 has been rarely reported in relatives of index cases.<sup>2,8</sup> Owing to the highly aggressive nature  
150 of the tumor, approximately half the patients have extraovarian spread at diagnosis.<sup>2</sup> The  
151 histopathological features include tumor cells in diffuse sheets with interspersed follicle-like  
152 spaces. The tumor cells are typically small round cells with hyperchromatic nuclei and scant  
153 to moderate amount of cytoplasm. Approximately 50% of the cases exhibit large cell  
154 morphology with nests and/or sheets of large cells with characteristic rhabdoid morphology.<sup>1</sup>  
155 Based on the genetic as well as the cytomorphologic resemblance of SCCOHT with  
156 malignant rhabdoid tumors elsewhere in the body, it is often referred to as malignant rhabdoid  
157 tumor of the ovary. Intranuclear inclusions and intracytoplasmic hyaline globules have also  
158 been reported.<sup>8</sup>

159 SCCOHT is an aggressive tumor with a poor prognosis.<sup>2,9</sup> It usually presents at a  
160 higher stage with a 50% one year survival rate. Moreover, treatment strategies are not well  
161 standardized, owing to the rarity of the disease. However, most patients undergo surgical  
162 resection followed by chemotherapy, with neoadjuvant chemotherapy being given to reduce  
163 the bulk of the disease in selected cases.<sup>1,2</sup> The outcome is dismal for patients with extra-  
164 ovarian disease, where the disease proves fatal within 2 years.<sup>4</sup> Features associated with  
165 favourable prognosis in stage IA tumors include normal calcium levels at diagnosis, age more  
166 than 30 years, tumor size less than 10 cm and absence of large rhabdoid cells  
167 microscopically.<sup>2</sup> Several chemotherapy protocols have been used, with variable success  
168 rates, including those used in the treatment of malignant surface epithelial ovarian tumors and  
169 malignant germ cell tumors. Commonly employed regimens include, (a) cyclophosphamide,  
170 doxorubicin with or without cisplatin, and hexamethylmelamine; (b) paclitaxel in  
171 combination with cisplatin for advanced stages; (c) cisplatin, vinblastine, or bleomycin with  
172 etoposide regimens.<sup>10-12</sup> Radiation has been rarely used for such patients as is evidenced by



173 few previous reports, however, some of these studies have claimed better survival with  
174 radiotherapy.<sup>2,3,13</sup>

175 Only a few studies have reported the cytological features of SCCOHT, majority of  
176 which have described the intra-operative findings and cytology in body fluids.<sup>7,8,14-18</sup> Trichia  
177 *et al*, reported the cytologic features as seen on touch imprints prepared at the time of frozen  
178 section.<sup>8</sup> They described epithelial cells which were polygonal with round nuclei, mild to  
179 moderate nuclear atypia, indistinct nucleoli and moderate amount of vacuolated or  
180 eosinophilic cytoplasm.<sup>8</sup> To the best of our knowledge, ours is the first report to describe the  
181 cytological features of SCCOHT on fine needle aspiration cytology. Morphologic differential  
182 diagnoses commonly include granulosa cell tumor, small cell carcinoma ovary, pulmonary  
183 type (SCCOPT), dysgerminoma, non-Hodgkin's lymphoma and undifferentiated carcinoma.  
184 Some of the important features that can help in differentiating these tumors from SCCOHT  
185 have been listed in table 1.<sup>8,9,14-18</sup>

186 To conclude, SCCOHT is a rare malignancy, predominantly affecting younger  
187 women. It carries a poor prognosis and management requires prompt diagnosis followed by  
188 aggressive multimodality treatment. A high index of clinical suspicion, especially in young  
189 women with abdomino-pelvic masses and hypercalcemia, and knowledge of its characteristic  
190 cytologic, histopathologic and immunohistochemical features can help in timely diagnosis  
191 and appropriate treatment, which might help in improving the survival in such patients.

192 **Author disclosure statement:** No competing financial interests exist.

193 **Acknowledgement:** We would like to acknowledge Dr Jay Mehta, Consultant Pathologist at  
194 the Centre of Excellence in Histopathology, at SRL Diagnostics, Mumbai, India, for his help  
195 in performing the BRG1 immunohistochemistry.

196 **References**

- 197 1. Khosla D, Gupta N, Koshy A, et al. Ovarian Small Cell Carcinoma of Hypercalcemic  
198 Type in an Adolescent Girl. *J Obstet Gynaecol India*. 2019;69(Suppl 1):60-62.
- 199 2. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic  
200 type. A clinicopathological analysis of 150 cases. *Am J Surg Pathol*. 1994;18:1102-  
201 16.
- 202 3. Dickersin GR, Kline IW, Scully RE. Small cell carcinoma of the ovary with  
203 hypercalcemia: a report of eleven cases. *Cancer*. 1982;49:188-97.
- 204 4. Korivi BR, Javadi S, Faria S, et al. Small Cell Carcinoma of the Ovary,  
205 Hypercalcemic Type: Clinical and Imaging Review. *Curr Probl Diagn Radiol*.  
206 2018;47:333-339.
- 207 5. Florell SR, Bruggers CS, Matlak M, et al. Ovarian small cell carcinoma of the  
208 hypercalcemic type in a 14 month old: the youngest reported case. *Med Pediatr*  
209 *Oncol*. 1999;32:304-7.
- 210 6. Witkowski L, Goudie C, Foulkes WD, et al. Small-Cell Carcinoma of the Ovary of  
211 Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with  
212 Recent Developments on Pathogenesis. *Surg Pathol Clin*. 2016;9:215-26.
- 213 7. Abrams J, Silverberg SG. The role of intra-operative cytology in the evaluation of  
214 gynaecologic disease. *Pathol Annu*. 1989;24:167-187.
- 215 8. Trichia HJ, Tziakou P, Papatheodorou DC, et al. Cytological Features of the Large  
216 Cell Variant of Small Cell Ovarian Carcinoma in Young Patients with  
217 Hypercalcemia: Histological Findings and Review of the Literature. *Acta Cytol*.  
218 2017;61:462-468.

- 219 9. Ghazi A, Ayaz A, Hamid T, et al. Small cell carcinoma of the ovary hypercalcemic  
220 type (SCCOHT): A rare case after in vitro fertilization. *Pak J Med Sci.* 2017;33:241-  
221 244.
- 222 10. Inadome Y, Shibata T, Suzuki K, Tsugata M, Shimabukuro K, Noguchi M.  
223 Hypercalcemic-type ovarian small cell carcinoma with unique CD34  
224 expression. *Pathology International.* 2009;59:766-768.
- 225 11. Lamovec J, Bracko M, Cerar O. Familial occurrence of small-cell carcinoma of the  
226 ovary. *Archives of Pathology and Laboratory Medicine.* 1995;119:523-527.
- 227 12. Fignon A, Fetissof F, Calais G, et al. Small cell carcinoma of the ovary. A clinical and  
228 pathological entity-anotomo. *Journal de Gynecologie, Obstetrique et Biologie de la*  
229 *Reproduction.* 1993;22:372-378.
- 230 13. Harrison ML, Hoskins P, Du Bois A, et al. Small cell of the ovary, hypercalcemic  
231 type-analysis of combined experience and recommendation for management. A GCIG  
232 study. *Gynecologic Oncology.* 2006;100:233-238.
- 233 14. Dharan M. Intraoperative cytology of small cell carcinoma of the ovary with  
234 hypercalcemia. A case report. *Acta Cytol.* 1993;37:61-66.
- 235 15. Laé M, Bourgoin R, Cornelis F, et al. Cytological features of small cell carcinoma of  
236 the ovary-hypercalcemic type/malignant ovarian rhabdoid tumor in ascitic fluid.  
237 *Diagn Cytopathol.* 2018;46:365-6.
- 238 16. Selvaggi SM. Small-cell carcinoma of the ovary in peritoneal fluid. *Diagn Cytopathol.*  
239 1994;11:266-70.
- 240 17. Jazaerly T, Jaratli H, Jacques SM, et al. Small cell carcinoma of the ovary presenting  
241 in a urine cytology specimen: a case report. *Acta Cytol.* 2011;55:291-5.

- 242 18. Lavrut PM, Le Loarer F, Normand C, et al. Small Cell Carcinoma of the Ovary,  
243 Hypercalcemic Type: Report of a Bilateral Case in a Teenager Associated with  
244 SMARCA4 Germline Mutation. *Pediatr Dev Pathol.* 2016;19:56-60.

Journal Pre-proof

245 **Table 1: Histopathologic mimics of small cell carcinoma of ovary, hypercalcemic type**  
 246 **and their characteristic features**

<b>Tumor</b>	<b>Age range</b>	<b>Gross appearance</b>	<b>Architecture</b>	<b>Cell characteristics</b>	<b>Immunohistochemistry</b>
<b>SCCOHT</b>	Less than 40 years	Large predominantly solid tumors. Necrosis, haemorrhage and cystic degeneration- common	Diffuse sheets with interspersed follicle-like spaces	Small round cells with hyperchromatic nuclei and scant amount of cytoplasm	WT1, CK, EMA, CD10, calretinin-positive; Inhibin-negative
<b>Juvenile Granulosa cell tumor</b>	Mostly children; wide age range	Solid- cystic with tan to yellow appearance.	Diffuse sheets, insular pattern, Call-Exner bodies	Uniform pale round nuclei with nuclear grooves and scant pale cytoplasm	Inhibin, calretinin, FOXL2, WT1, CD56- positive; CK7, EMA-negative
<b>SCCOPT</b>	Postmenopausal	Large predominantly solid tumors with frequent necrosis.	Diffuse sheets. Most have a component of surface epithelial tumor.	Small round cells with moulding, salt and pepper chromatin and scant cytoplasm	Chromogranin, synaptophysin, CD56- variable positivity; CK- +/-
<b>Dysgerminoma</b>	Children and young women	Solid, fleshy tan or white cut surface. Haemorrhage, necrosis, cystic degeneration- may be present	Sheets and nests, interspersed by fibrous septae containing lymphocytes	Medium sized nuclei with vesicular chromatin, prominent nucleoli, abundant eosinophilic to clear cytoplasm and distinct cell borders	PLAP, C117, D2-40, OCT-4, SALL4-positive; EMA- negative
<b>NHL</b>	Wide age range	Solid, fleshy to firm and rubbery. Haemorrhage, necrosis, cystic degeneration- in minority	Diffuse sheets (architecture varies depending on type of lymphoma)	Medium to large sized, coarse chromatin, conspicuous nucleoli and scant amount of cytoplasm	CD45- positive; WT1, CK, EMA, CD117-negative


247 \*SCCOHT: small cell carcinoma of ovary, hypercalcemic type; SCCOPT: small cell  
 248 carcinoma of ovary, pulmonary type; NHL: non-Hodgkin's lymphoma


249 **Figure Legends**

250 **Figure 1:** A-C: Smears from the pelvic mass showing tumor cells in clusters and scattered  
251 singly, with moderate nuclear pleomorphism, coarse clumped chromatin and moderate  
252 amount of cytoplasm (May Grunwald Giemsa; A: 10x; B: 20x; C: H&E, 20x); D-F: Sections  
253 from cell block showing areas of necrosis and similar morphology of tumor cells with some  
254 cells having rhabdoid appearance (H&E; D:4x, E:40x, F:40x); G-I: Immunocytochemistry on  
255 cell-block showing tumor cells to be positive for vimentin (G: 10x), para-nuclear dot-like  
256 positivity for CD99 (H: 20x) and negative for myogenin (I: 20x)

257 **Figure 2:** A, B: Gross specimen showing the tumor with bosselated outer surface and solid-  
258 cystic cut surface. Cut surface is lobulated with greyish-white solid areas, areas of necrosis  
259 and haemorrhage

260 **Figure 3:** A-C: Sections from ovarian mass showing tumor arranged in sheets, lobules and  
261 follicle-like spaces with intervening areas of necrosis. Tumor cells have similar morphology  
262 as seen on the aspirate smears (H&E; A: 4x; B: 20x); C: Section showing omental deposits  
263 (H&E; 4x). D-I: Immunohistochemistry showing tumor cells to be positive for CK (D: 20x),  
264 Vimentin (E: 20x), WT1 (F: 20x) with retained INI1 expression (G: 20x) and loss of nuclear  
265 expression of BRG1 (H:20x) and negative for chromogranin (I: 20x)





Journal Pre



